Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubrogepant in the Acute Treatment of Migraine in Children and Adolescents
NCT05125302Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of ubrogepant in migraine, sponsored by AbbVie Inc.. Started Jan 2022; status: recruiting.
02
Drugs
ubrogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05125302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125302.